Legionella Infections¶
Chapter 164 | Part 5: Infectious Diseases · Part 5 – Infectious Diseases: Bacterial · Chapter 164
Key Clinical Points¶
- Legionella species cause two primary diseases: Legionnaires' disease (severe pneumonia) and Pontiac fever (mild, self-limited illness).
- L. pneumophila serotype 1 is responsible for >80% of Legionnaires' disease cases.
- Diarrhea, hyponatremia, and confusion are strong predictors of Legionella pneumonia compared to other atypical pneumonias.
- Urinary antigen testing detects only L. pneumophila serotype 1 (sensitivity ~70%, specificity high).
- Culture on BCYE agar is the gold standard but requires 3-5 days for growth; essential for outbreak investigation.
- First-line treatment for Legionnaires' includes macrolides (azithromycin, clarithromycin) or fluoroquinolones (levofloxacin, moxifloxacin, ciprofloxacin).
- Pontiac fever does not require antibiotics and resolves spontaneously.
- Outbreaks are linked to water sources such as cooling towers, fountains, and spa systems.
- Risk factors include age >40 years, male sex, smoking, and immunocompromise.
- Case-fatality rate is ~10% for Legionnaires' disease; 30-50% in immunocompromised patients or those with severe lung disease.
1. DEFINITION & OVERVIEW¶
Legionella species cause two distinct clinical syndromes:
• Legionnaires' disease: Severe pneumonia with systemic symptoms (fever, confusion, diarrhea) • Pontiac fever: Mild, self-limited influenza-like illness without pneumonia • Extrapulmonary disease: Rare presentations including endocarditis and septic arthritis
Definition (Harrison's 22e): Legionella species are responsible for >50% of all waterborne outbreaks and >10% of disease related to drinking water in the United States.
1.1 Disease Classification¶
• Legionnaires' disease: Severe pneumonia with systemic symptoms • Pontiac fever: Self-limited influenza-like illness without pneumonia • Extrapulmonary manifestations: ◦ Skin/soft tissue infections (cellulitis-like) ◦ Endocarditis (prosthetic valve) ◦ Myocarditis/pericarditis ◦ Septic arthritis/sinusitis
2. EPIDEMIOLOGY¶
• Incidence: 50,000-70,000 cases of Legionnaires' disease annually in the US • Trends: Significant increase noted since 2014 (Figure 164-1) • Dominant Strain: L. pneumophila serotype 1 accounts for >80% of human cases • Seasonality: Increased incidence during summer/fall due to higher temperature and humidity
Table 164-1 highlights the variety of common-source outbreaks (2012-2022) involving sites like hotels, hospitals, and communities. Sources include potable water, fountains, spa systems, cooling towers, and hot-tub displays.
2.1 Risk Factors¶
• Age: >40 years (highest risk for complications) • Sex: Male sex (3x higher risk than females) • Smoking: Dose-dependent risk; impairs airway defenses • Chronic Disease: COPD, emphysema, renal/hepatic/cardic disease • Immunocompromise: ◦ Cancer patients ◦ Solid organ transplant recipients ◦ Glucocorticoid use (prednisone) ◦ TNF inhibitor therapy • Genetics: Polymorphisms in innate immune genes
3. ETIOLOGY & PATHOPHYSIOLOGY¶
• Microbiology: Aerobic gram-negative bacteria; found in aquatic environments and soil • Life Cycle: ◦ Replicative phase (nutrient-rich/protozoa) ◦ Noninfective transmissive phase (resource scarcity) • Transmission: Inhalation or aspiration of aerosolized particles (<10 μm diameter) • Pathogenesis: ◦ Phagocytosis by alveolar macrophages ◦ Evasion of lysosomal degradation ◦ Intracellular replication in human cells ◦ Immune response involving interferon γ and neutrophil recruitment
3.1 Transmission Dynamics¶
• Primary Routes: ◦ Domestic: Showerheads/sinks ◦ Community: Cooling towers, fountains ◦ Healthcare: Facility water systems • Attack Rates: ◦ Legionnaires' disease: ~5% among exposed individuals ◦ Pontiac fever: ~90% among exposed individuals
4. CLINICAL FEATURES¶
Table 164-2 compares the clinical profiles of Legionnaires' disease and Pontiac fever:
• Legionnaires' Disease: ◦ Incubation: 2–10 days ◦ Symptoms: Fever, confusion, diarrhea, myalgias, shortness of breath, abdominal or chest pain, cough, sputum production ◦ Severity: >90% hospitalization rate; 30-50% ICU admission; ~10% case-fatality • Pontiac Fever: ◦ Incubation: 24–72 h ◦ Symptoms: Fever, headache, myalgias, nausea/vomiting, fatigue, vertigo ◦ Severity: <1% hospitalization rate; extremely low ICU/fatality rates
4.1 Clinical Indicators¶
• Key Predictors: Presence of diarrhea, hyponatremia, and confusion strongly suggests Legionella over other atypical pneumonias • Radiographic Findings: ◦ CXR: Consolidation (often lower lobe, but can be upper lobe in immunocompromised hosts) ◦ CT: Airspace disease with ground-glass opacities; may show nodules or cavitation in immunocompromised patients (Figures 3, 4, 5)
5. DIFFERENTIAL DIAGNOSIS¶
• Primary Differentials: ◦ Mycoplasma pneumoniae ◦ Chlamydia pneumoniae ◦ Pneumocystis jirovecii (in immunocompromised hosts) • Diagnostic Challenges: ◦ Non-specific initial symptoms ◦ Overlap with other atypical pneumonias ◦ Limited rapid testing in primary care
5.1 CDC Reporting Criteria¶
• Presumptive case: Legionnaires' disease developing after ≥10 days of hospitalization • Possible case: Legionnaires' disease with <10 days of hospitalization prior to symptom onset • Outbreak Investigation Required: ◦ Any presumptive case in a healthcare facility ◦ Two or more possible cases within 12 months
6. INVESTIGATIONS & DIAGNOSIS¶
- Radiology:
- CXR: Identify consolidation/infiltrates (e.g., Figure 3, 4)
- CT: Assess extent of disease and identify complications like cavitation or nodules (Figure 5)
- Culture:
- Method: BCYE agar
- Timing: 3-5 days for growth
- Role: Gold standard; essential for serotyping and outbreak investigation3. Urinary Antigen:
- Target: L. pneumophila serotype 1 only
- Performance: Sensitivity ~70%, high specificity
- Molecular Testing:
- Method: PCR (e.g., on bronchoalveolar lavage fluid)
- Role: Useful for non-serotype 1 strains and extrapulmonary disease
7. MANAGEMENT & TREATMENT¶
- Pontiac Fever:
- Treatment: Supportive care only (no antibiotics required)
- Legionnaires' Disease:
- First-line options: Macrolides or Fluoroquinolones
- Macrolide Options (Table 164-3): ◦ Azithromycin: 500 mg PO once daily (day 1), followed by 250 mg PO once daily for ≥4 days ◦ Clarithromycin: 400 mg PO daily
- Fluoroquinolone Options (Table 164-3): ◦ Levofloxacin: 750 mg PO once daily ◦ Ciprofloxacin: 500 mg PO twice daily ◦ Moxifloxacin: 400 mg PO once daily
- Duration:
- 5-10 days for stable patients
- Special Populations:
- Immunocompromised: May require longer treatment duration
- Extrapulmonary disease: Same antimicrobial regimens as pneumonia
8. PROGNOSIS & COMPLICATIONS¶
• Case-fatality rate: ◦ Overall: ~10% ◦ Immunocompromised/Severe Lung Disease: 30-50% • Clinical Complications: ◦ Acute respiratory failure ◦ Septic shock ◦ Multiorgan failure • Mortality Risk Factors: ◦ Age >65 years ◦ Chronic lung disease ◦ Immunocompromise ◦ Delayed diagnosis/treatment
9. SPECIAL CONSIDERATIONS¶
• Outbreak Management: ◦ Immediate investigation for presumptive healthcare-associated cases ◦ Environmental sampling of water systems (cooling towers, showers) ◦ Molecular typing to identify common-source outbreaks ◦ Public health interventions: chlorination, temperature control, biofilm removal • Prevention Strategies: ◦ Regular maintenance of building water systems ◦ Avoidance of stagnant water in unused plumbing ◦ Use of point-of-use filters in high-risk facilities
10. KEY PEARLS & CLINICAL TRAPS¶
• Diagnostic Clues: ◦ Presence of diarrhea and confusion are strong indicators for Legionella ◦ Urinalysis is insufficient for non-serotype 1 strains • Clinical Traps: ◦ Delayed diagnosis due to non-specific symptoms ◦ Over-reliance on urinary antigen without culture confirmation ◦ Underestimating risk in immunocompromised patients
Reference Tables¶
TABLE 164-1 Examples of Legionella Common Source Outbreaks, Indicating the Wide Variety of Sources and Cases a SITE…¶
Harrison's 22e, p.1271
| SITE | YEAR | ORGANISMa | REPORTED SOURCE(S) | CASES |
|---|---|---|---|---|
| Hotelb | 2012 | L. pneumophila serotype 1 | Potable water, fountain, spa | 85 (29 suspect) |
| 2012 | L. pneumophila | Potable water | ||
| Communityd | 2014 | L. pneumophila serotype 1 | Cooling tower | 334 cases |
| 2014-15 | L. pneumophila | Potable water, household, cooling towers |
||
| Long-term care facilityf | 2015 | L. pneumophila | Potable water | 74 cases |
| 2015 | L. pneumophila | Hotel cooling towers | ||
| Hospitalh | 2018 | L. pneumophila serotype 1 | Potable water, showers | 13 cases |
| 2019 | L. pneumophila | Fountain | ||
| Communityj | 2019 | L. pnuemophilak | Hot-tub display | 141 cases |
| 2022 | L. pneumophila serotype 1 | Cooling tower |
TABLE 164-2 Clinical and Epidemiologic Features of Legionella Pneumonia (Legionnaires’ Disease) and Pontiac Fever…¶
Harrison's 22e, p.1272
| FEATURE | LEGIONELLA PNEUMONIA |
PONTIAC FEVER |
|---|---|---|
| Incubation period | 2–10 daysa | 24–72 h |
| Legionella infection | ||
| Common symptoms | Abdominal or chest pain Anorexia Cough, sputum production Confusionb Diarrheab Fatigue Fever/chills Headache Myalgias Nausea/vomitingb Shortness of breath |
Cough Diarrhea Fatigue Fever/chills Headache Myalgias Nausea/vomiting Vertigo |
| Age >40 years Male Smoker Immunosuppressed host Neurologic disease Chronic lung disease Organ dysfunction/ chronic illness |
||
| Attack rate among exposed individuals |
~5%c | ~90% |
| >90% | ||
| ICU admission rate | 30–50% | Extremely low |
| Antibiotics (macrolide or fluoroquinolone) |
||
| Case-fatality rated | 10% | Extremely low |
TABLE 164-3 Legionella Treatment Options DISEASE Pontiac fever Legionella pneumonia¶
Harrison's 22e, p.1275
| DISEASE | DISEASE SEVERITY | |
|---|---|---|
| MILD | MODERATE/SEVEREa,b | |
| Pontiac fever | None | N/A |
| A) Fluoroquinolone: Levofloxacin, 750 mg PO once daily or Ciprofloxacin, 500 mg PO twice daily or Moxifloxacin, 400 mg PO once daily or B) Macrolide: Azithromycin, 500 mg PO once daily (day 1), followed by 250 mg PO once daily (for minimum of 4 days) or Clarithromycin, 400 mg PO daily |